Anas Younes, MD

Articles

Diffuse Large B-Cell Lymphoma: Changing Treatment Paradigms

April 15th 2014

With the progress in diagnostic methods that has made it possible to decipher the genetic code of DLBCL within a relatively short time, and with the increasing number of drugs that are entering clinical trials, our next big challenge is to enroll patients in trials in a timely manner.

ACR Appropriateness Criteria® Localized Nodal Indolent Lymphoma

Bradford S. Hoppe, MD, MPH;David C. Hodgson, MD;Ranjana H. Advani, MD;Bouthaina S. Dabaja, MD;Christopher R. Flowers, MD, MS;Chul Soo Ha, MD;Monika L. Metzger, MD;John P. Plastaras, MD, PhD;Kenneth B. Roberts, MD;Ronald Shapiro, MD;Stephanie A. Terezakis, MD;Karen M. Winkfield, MD, PhD;Anas Younes, MD;Louis S. Constine, MD

August 15th 2013

The present guidelines review epidemiology, pathology, presentation, workup, staging, prognostic factors, and treatment options for patients with localized nodal indolent lymphoma, with an emphasis on radiation guidelines, including radiation dose, field design, and radiation techniques.

Using Social Media in Oncology for Education and Patient Engagement

Michael A. Thompson, MD, PhD;Anas Younes, MD;Robert S. Miller, MD, FACP

September 12th 2012

We presented an interactive session entitled “Using Social Media in Oncology for Education and Patient Engagement” at the American Society of Clinical Oncology (ASCO) 2012 Annual Meeting. This article summarizes the points made in those presentations.

Irinotecan in Relapsed or Refractory Non-Hodgkin’s Lymphoma

Andreas H. Sarris, MD, PhD;Jorge Romaguera, MD;Fredrick B. Hagemeister, MD;Maria A. Rodriguez, MD;Peter Mclaughlin, MD;Barbara Pro, MD;Anas Younes, MD;Ofie Mesina, RN;Fernando Cabanillas, MD;L. Jeffrey Medeiros, MD;Barry Samuels, MD

July 1st 2001

Irinotecan (CPT-11, Camptosar) is a topoisomerase I inhibitor with a broad spectrum of antitumor clinical activity. Various schedules and doses have been studied, and major complications were delayed diarrhea and